A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer

Shirin Shafazand, Michael K. Gould

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

INTRODUCTION: Estimating the clinical probability of mediastinal metastasis in patients with non-small cell lung cancer (NSCLC) can facilitate the selection and interpretation of staging tests. PURPOSE: We sought to identify independent clinical predictors of mediastinal metastasis and to develop a prediction rule to estimate the pretest probability of nodal metastasis in patients with NSCLC. METHODS: We used data from a randomized controlled trial of selective versus routine mediastinoscopy to develop a clinical prediction model. RESULTS: Five hundred sixty-six patients were included, with a mean age of 65 ± 9 years; 31% had positive lymph nodes. Independent predictors of positive nodes included adenocarcinoma or large cell histology (OR 2.6, 95% confidence interval [CI] = 1.8-3.9), apparent metastatic disease on chest radiography (OR 2.4, 95% CI = 1.2-4.7), central location of the primary tumor (OR 2.1, 95% CI = 1.4-3.3), symptoms from the primary tumor (OR 1.6, 95% CI = 1.1-2.4), tumor diameter ≥3.6 cm (OR 1.5, 95% CI = 1.0-2.3), and age less than 65 years (OR 1.5, 95% CI = 1.0-2.2). Model accuracy and calibration were good, with an area under the receiver operating characteristic curve of 0.70 (95% CI = 0.66-0.75) and good agreement between observed and predicted probabilities of mediastinal metastasis. CONCLUSIONS: Our prediction rule can be used to estimate the pretest probability of mediastinal metastasis in patients with NSCLC. Such estimates can facilitate clinical decision making when selecting and interpreting the results of noninvasive and invasive staging tests.

Original languageEnglish
Pages (from-to)953-959
Number of pages7
JournalJournal of Thoracic Oncology
Volume1
Issue number9
DOIs
StatePublished - Nov 1 2006

Fingerprint

Decision Support Techniques
Non-Small Cell Lung Carcinoma
Confidence Intervals
Neoplasm Metastasis
Mediastinoscopy
Neoplasms
Radiography
ROC Curve
Calibration
Histology
Adenocarcinoma
Thorax
Randomized Controlled Trials
Lymph Nodes

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer. / Shafazand, Shirin; Gould, Michael K.

In: Journal of Thoracic Oncology, Vol. 1, No. 9, 01.11.2006, p. 953-959.

Research output: Contribution to journalArticle

@article{437c91915e724b2aa2378fa9323a9318,
title = "A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer",
abstract = "INTRODUCTION: Estimating the clinical probability of mediastinal metastasis in patients with non-small cell lung cancer (NSCLC) can facilitate the selection and interpretation of staging tests. PURPOSE: We sought to identify independent clinical predictors of mediastinal metastasis and to develop a prediction rule to estimate the pretest probability of nodal metastasis in patients with NSCLC. METHODS: We used data from a randomized controlled trial of selective versus routine mediastinoscopy to develop a clinical prediction model. RESULTS: Five hundred sixty-six patients were included, with a mean age of 65 ± 9 years; 31{\%} had positive lymph nodes. Independent predictors of positive nodes included adenocarcinoma or large cell histology (OR 2.6, 95{\%} confidence interval [CI] = 1.8-3.9), apparent metastatic disease on chest radiography (OR 2.4, 95{\%} CI = 1.2-4.7), central location of the primary tumor (OR 2.1, 95{\%} CI = 1.4-3.3), symptoms from the primary tumor (OR 1.6, 95{\%} CI = 1.1-2.4), tumor diameter ≥3.6 cm (OR 1.5, 95{\%} CI = 1.0-2.3), and age less than 65 years (OR 1.5, 95{\%} CI = 1.0-2.2). Model accuracy and calibration were good, with an area under the receiver operating characteristic curve of 0.70 (95{\%} CI = 0.66-0.75) and good agreement between observed and predicted probabilities of mediastinal metastasis. CONCLUSIONS: Our prediction rule can be used to estimate the pretest probability of mediastinal metastasis in patients with NSCLC. Such estimates can facilitate clinical decision making when selecting and interpreting the results of noninvasive and invasive staging tests.",
author = "Shirin Shafazand and Gould, {Michael K.}",
year = "2006",
month = "11",
day = "1",
doi = "10.1097/01243894-200611000-00006",
language = "English",
volume = "1",
pages = "953--959",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "9",

}

TY - JOUR

T1 - A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer

AU - Shafazand, Shirin

AU - Gould, Michael K.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - INTRODUCTION: Estimating the clinical probability of mediastinal metastasis in patients with non-small cell lung cancer (NSCLC) can facilitate the selection and interpretation of staging tests. PURPOSE: We sought to identify independent clinical predictors of mediastinal metastasis and to develop a prediction rule to estimate the pretest probability of nodal metastasis in patients with NSCLC. METHODS: We used data from a randomized controlled trial of selective versus routine mediastinoscopy to develop a clinical prediction model. RESULTS: Five hundred sixty-six patients were included, with a mean age of 65 ± 9 years; 31% had positive lymph nodes. Independent predictors of positive nodes included adenocarcinoma or large cell histology (OR 2.6, 95% confidence interval [CI] = 1.8-3.9), apparent metastatic disease on chest radiography (OR 2.4, 95% CI = 1.2-4.7), central location of the primary tumor (OR 2.1, 95% CI = 1.4-3.3), symptoms from the primary tumor (OR 1.6, 95% CI = 1.1-2.4), tumor diameter ≥3.6 cm (OR 1.5, 95% CI = 1.0-2.3), and age less than 65 years (OR 1.5, 95% CI = 1.0-2.2). Model accuracy and calibration were good, with an area under the receiver operating characteristic curve of 0.70 (95% CI = 0.66-0.75) and good agreement between observed and predicted probabilities of mediastinal metastasis. CONCLUSIONS: Our prediction rule can be used to estimate the pretest probability of mediastinal metastasis in patients with NSCLC. Such estimates can facilitate clinical decision making when selecting and interpreting the results of noninvasive and invasive staging tests.

AB - INTRODUCTION: Estimating the clinical probability of mediastinal metastasis in patients with non-small cell lung cancer (NSCLC) can facilitate the selection and interpretation of staging tests. PURPOSE: We sought to identify independent clinical predictors of mediastinal metastasis and to develop a prediction rule to estimate the pretest probability of nodal metastasis in patients with NSCLC. METHODS: We used data from a randomized controlled trial of selective versus routine mediastinoscopy to develop a clinical prediction model. RESULTS: Five hundred sixty-six patients were included, with a mean age of 65 ± 9 years; 31% had positive lymph nodes. Independent predictors of positive nodes included adenocarcinoma or large cell histology (OR 2.6, 95% confidence interval [CI] = 1.8-3.9), apparent metastatic disease on chest radiography (OR 2.4, 95% CI = 1.2-4.7), central location of the primary tumor (OR 2.1, 95% CI = 1.4-3.3), symptoms from the primary tumor (OR 1.6, 95% CI = 1.1-2.4), tumor diameter ≥3.6 cm (OR 1.5, 95% CI = 1.0-2.3), and age less than 65 years (OR 1.5, 95% CI = 1.0-2.2). Model accuracy and calibration were good, with an area under the receiver operating characteristic curve of 0.70 (95% CI = 0.66-0.75) and good agreement between observed and predicted probabilities of mediastinal metastasis. CONCLUSIONS: Our prediction rule can be used to estimate the pretest probability of mediastinal metastasis in patients with NSCLC. Such estimates can facilitate clinical decision making when selecting and interpreting the results of noninvasive and invasive staging tests.

UR - http://www.scopus.com/inward/record.url?scp=34247882833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247882833&partnerID=8YFLogxK

U2 - 10.1097/01243894-200611000-00006

DO - 10.1097/01243894-200611000-00006

M3 - Article

C2 - 17409978

AN - SCOPUS:34247882833

VL - 1

SP - 953

EP - 959

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 9

ER -